权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Protein Replacement Drug for Friedreichs Ataxia

弗里德赖希共济失调的蛋白质替代药物

基本信息

批准号：
9551920
负责人：
Elizabeth Ottinger
金额：
$ 245.31万
依托单位：
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9551920
关键词：
Affect Age Alpha Cell Anabolism Animal Model Biochemical Biological Assay Blindness Cardiac Cell model Cessation of life Childhood Defect Development Diabetes Mellitus Disease Electron Transport Friedreich Ataxia Genes Heart failure Hemophilia A Hereditary Disease Histology Homeostasis Investigational New Drug Application Iron Iron-Sulfur Proteins Lead Longevity Metabolic Diseases Mitochondria Mitochondrial Diseases Mitochondrial Matrix Nervous System Physiology Patients Peptides Pharmaceutical Preparations Production Proteins Recombinant Fusion Proteins Research Personnel Skeletal Muscle Spinal Curvatures Sulfur Supportive care System Technology Therapeutics for Rare and Neglected Diseases Toxicology United States Food and Drug Administration Walking Work disease phenotype enzyme replacement therapy experience frataxin hearing impairment improved mouse model premature prevent scoliosis tat Protein

项目摘要

Friedreichs Ataxia (FA) is a rare genetic disease caused by repetitions in the gene that prevent production of the mitochondrial matrix protein frataxin (FXN), which functions in mitochondrial iron homeostasis, notably in the de novo biosynthesis of iron-sulfur cluster proteins. In its absence, free iron accumulates in mitochondria, iron-sulfur proteins lose activity and energy production fails through damage to the electron transport chain. The lead investigator has developed a protein replacement approach that uses a cell-penetrant peptide to deliver functional FXN to the mitochondrial matrix. Protein replacement therapy is a well-established approach to metabolic diseases, such as diabetes, lysosomal storage disorders and hemophilia. Work in patient-derived cellular and animal models has demonstrated that replacement of functional FXN using the peptide TAT can correct the FA disease phenotype. In a mouse model, TAT-FXN extends lifespan, corrects histology and biochemical defects, and improves cardiac and neurological function. Moreover, this TAT-protein delivery platform could be extended beyond FA, representing a technology with the potential to treat multiple mitochondrial disorders for which there are no current therapies. The TRND project team are collaborating to develop and manufacture the recombinant fusion protein CTI-1601, conducting additional efficacy and toxicology studies, and developing and validating the biochemical assays necessary to evaluate CTI-1601. Successful completion of these studies will enable the collaborator to submit an Investigational New Drug application to the Food and Drug Administration.

Friedreichs共济失调（FA）是一种罕见的遗传性疾病，由阻止线粒体基质蛋白共济失调蛋白（FXN）产生的基因重复引起，该蛋白在线粒体铁稳态中起作用，特别是在铁-硫簇蛋白的从头生物合成中。在缺乏铁的情况下，游离铁在线粒体中积累，铁硫蛋白失去活性，能量生产通过电子传递链的损伤而失败。首席研究员开发了一种蛋白质替代方法，该方法使用细胞渗透肽将功能性FXN递送到线粒体基质。蛋白质替代疗法是治疗代谢性疾病如糖尿病、溶酶体贮积症和血友病的成熟方法。在患者来源的细胞和动物模型中的工作已经证明，使用肽达特替换功能性FXN可以纠正FA疾病表型。在小鼠模型中，TAT-FXN延长寿命，纠正组织学和生化缺陷，并改善心脏和神经功能。此外，这种TAT蛋白递送平台可以扩展到FA之外，代表了一种有潜力治疗目前没有治疗方法的多种线粒体疾病的技术。 TRND项目组正在合作开发和生产重组融合蛋白CTI-1601，进行额外的疗效和毒理学研究，并开发和验证评估CTI-1601所需的生化测定。成功完成这些研究将使合作者能够向美国食品药品监督管理局提交研究性新药申请。